Blood Neutrophil to Lymphocyte Ratio as a Marker of Inflammatory Bowel Disease Severity in Iranian Adults: a Cross-Sectional Survey.

Parsia Noori Mirtaheri, Aria Shirani, Mobin Obeidinia, Elham Pishgar

Abstract read

In one paragraph

Article in Middle East journal of digestive diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Parsia Noori MirtaheriResearch Scholar, Medical Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0009-0006-5363-9029

Aria ShiraniCardiology Resident, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-4878-3721

Mobin ObeidiniaResearch Scholar, Gastrointestinal and Liver Diseases Research Center, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-3202-0041

Elham PishgarColorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-4154-3293

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Given the increase in the prevalence of inflammatory bowel diseases (IBD) in developing countries like Iran, studies to find new markers for disease monitoring seem necessary. Thus, we aimed to evaluate the value of a novel non-invasive marker, the neutrophil-to-lymphocyte ratio (NLR), in assessing the severity and activity of IBD in adults. Methods: We collected retrospective data from adult patients with a history of ulcerative colitis (UC) or Crohn's disease (CD) who attended the clinic, gathering information from one month prior to their enrollment. The data included demographics, the Mayo score (MS) for patients with UC, and the Crohn's Disease Activity Index (CDAI) for patients with CD, along with other inflammatory markers. Results: Of the 108 patients with IBD included in this study, 89 had UC, and 19 had CD. The NLR was significantly higher in patients with active disease than in those in remission, with Conclusion: The NLR is an effective marker for distinguishing between active and remissive patients with IBD and is closely associated with disease severity.

Indexed as

Blood neutrophile-to-lymphocyte ratioCrohn diseaseInflammatory bowel diseaseUlcerative colitis

Identifiers

PMID42903421

DOI10.34172/mejdd.3261

PMCPMC13680756

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.